Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-77c89778f8-rkxrd Total loading time: 0 Render date: 2024-07-21T18:54:15.715Z Has data issue: false hasContentIssue false

Topiramate

Published online by Cambridge University Press:  01 June 2018

Philip N. Patsalos  and
Erik K. St Louis
Philip N. Patsalos
Affiliation:
UCL Institute for Neurology
Erik K. St Louis
Affiliation:
Mayo Clinic
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
The Epilepsy Prescriber's Guide to Antiepileptic Drugs , pp. 301 - 313
Publisher: Cambridge University Press
Print publication year: 2018

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Suggested Reading

Ben-Menachem, E, Axelsen, M, Johanson, EH, Stagge, A, Smith, U. Predictors of weight loss in adults with topiramate-treated epilepsy. Obesity Research 2003; 11: 556–562.Google Scholar
Biton, V, Bourgeois, BF. Topiramate in patients with juvenile myoclonic epilepsy. Archives of Neurology 2005; 62: 1705–1708.CrossRefGoogle ScholarPubMed
Biton, V, Montouris, GD, Ritter, F, Riviello, JJ, Reife, R, Lim, P, Pledger, G. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group. Neurology 1999; 52: 1330–1337.CrossRefGoogle ScholarPubMed
Faught, E, Wilder, BJ, Ramsay, RE, Reife, RA, Kramer, LD, Pledger, GW, Karim, RM. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Topiramate YD Study Group. Neurology 1996; 46: 1684–1690.CrossRefGoogle ScholarPubMed
Glauser, TA, Clark, PO, Strawsburg, R. A pilot study of topiramate in the treatment of infantile spasms. Epilepsia 1998; 39: 1324–1328.Google Scholar
Groeper, K, McCann, ME. Topiramate and metabolic acidosis: a case series and review of the literature. Paediatric Anaesthesia 2005; 15: 167–170.CrossRefGoogle ScholarPubMed
Hamer, HM, Knake, S, Schomburg, U, Rosenow, F. Valproate-induced hyperammonemic encephalopathy in the presence of topiramate. Neurology 2000; 54: 230–232.Google Scholar
Hernandez-Diaz, S, Smith, CR, Shen, A, Mittendorf, R, Hauser, WA, Yerby, M, Holmes, LB. Comparative safety of antiepileptic drugs during pregnancy. Neurology 2012; 78: 1692–1699.CrossRefGoogle ScholarPubMed
Johannessen Landmark, C, Patsalos, PN. Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Reviews in Neurotherapeutics 2010; 10: 119–140.Google Scholar
Marson, AG, Al-Kharusi, AM, Alwaidh, M, et al.; SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet 2007; 369: 1000–1015.CrossRefGoogle ScholarPubMed
Marson, AG, Al-Kharusi, AM, Alwaidh, M, et al.; SANAD Study group. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 2007; 369: 1016–1026.Google Scholar
Meador, KJ, Loring, DW, Hulihan, JF, Kamin, M, Karim, R. Differential cognitive and behavioral effects of topiramate and valproate. Neurology 2003; 60: 1483–1488.CrossRefGoogle ScholarPubMed
Meador, KJ, Loring, DW, Vahle, VJ, Ray, PG, Werz, MA, Fessler, AJ, Ogrocki, P, Schoenberg, MR, Miller, JM, Kustra, RP. Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers. Neurology 2005; 64: 2108–2114.CrossRefGoogle ScholarPubMed
Mirza, N, Marson, AG, Pirmohamed, M. Effect of topiramate on acid–base balance: extent, mechanism and effects. British Journal of Clinical Pharmacology 2009; 68: 655–661.CrossRefGoogle ScholarPubMed
Mula, M, Trimble, MR, Thompson, P, Sander, JW. Topiramate and word-finding difficulties in patients with epilepsy. Neurology 2003; 60: 1104–1107.CrossRefGoogle ScholarPubMed
Nallani, SC, Glauser, TA, Hariparsad, N, Setchell, K, Buckley, DJ, Buckley, AR, Desai, PB. Dose-dependent induction of cytochrome P450 (CYP) 3A4 and activation of pregnane X receptor by topiramate. Epilepsia 2003; 44: 1521–1528.Google Scholar
Ohman, I, Sabers, A, de Flon, P, Luef, G, Tomson, T. Pharmacokinetics of topiramate during pregnancy. Epilepsy Research 2009; 87: 124–129.CrossRefGoogle ScholarPubMed
Patsalos, PN. Antiepileptic drug interactions: a clinical guide, 3rd edition. Springer, London, UK; 2016.CrossRefGoogle Scholar
Patsalos, PN, Berry, DJ. Therapeutic drug monitoring of antiepileptic drugs by use of saliva. Therapeutic Drug Monitoring 2013; 35: 4–29.CrossRefGoogle ScholarPubMed
Privitera, M, Fincham, R, Penry, J, Reife, R, Kramer, L, Pledger, G, Karim, R. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages. Topiramate YE Study Group. Neurology 1996; 46: 1678–1683.Google Scholar
Pulman, J, Jette, N, Dykeman, J, Hemming, K, Hutton, JL, Marson, AG. Topiramate add-on for drug-resistant partial epilepsy. Cochrane Database Systematic Review 2014; 2: CD001417.Google Scholar
Sachdeo, RC, Glauser, TA, Ritter, F, Reife, R, Lim, P, Pledger, G. A double-blind, randomized trial of topiramate in Lennox–Gastaut syndrome. Neurology 1999; 52: 1882–1887.Google Scholar
St. Louis, EK, Gidal, BE, Henry, TR, Kaydanova, Y, Krumholz, A, McCabe, PH, Montouris, GD, Rosenfeld, WE, Smith, BJ, Stern, JM, Waterhouse, EJ, Schulz, RM, Garnett, WR, Bramley, T. Conversions between monotherapies in epilepsy: expert consensus. Epilepsy and Behavior 2007; 11: 222–234.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×